Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout
Willburger, R. E., Mysler, E., Derbot, J., Jung, T., Thurston, H., Kreiss, A., Litschig, S., Krammer, G., Tate, G. A.
Published in Rheumatology (Oxford, England) (01.07.2007)
Published in Rheumatology (Oxford, England) (01.07.2007)
Get full text
Journal Article
The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors
Pagano, Adriana, Rüegg, Doris, Litschig, Stephane, Stoehr, Natacha, Stierlin, Christine, Heinrich, Micheline, Floersheim, Philipp, Prezèau, Laurent, Carroll, Fiona, Pin, Jean-Philippe, Cambria, Antonio, Vranesic, Ivo, Flor, Peter Josef, Gasparini, Fabrizio, Kuhn, Rainer
Published in The Journal of biological chemistry (27.10.2000)
Published in The Journal of biological chemistry (27.10.2000)
Get full text
Journal Article
CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding
Litschig, S, Gasparini, F, Rueegg, D, Stoehr, N, Flor, P J, Vranesic, I, Prézeau, L, Pin, J P, Thomsen, C, Kuhn, R
Published in Molecular pharmacology (01.03.1999)
Get full text
Published in Molecular pharmacology (01.03.1999)
Journal Article
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib
Lehmann, Reiner, Brzosko, Marek, Kopsa, Petr, Nischik, Ruth, Kreiss, Andreas, Thurston, Helen, Litschig, Stephane, Sloan, Victor S.
Published in Current medical research and opinion (01.04.2005)
Published in Current medical research and opinion (01.04.2005)
Get full text
Journal Article